Brian Ayuste, MD
Nephrology · Newhall
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 21 years
- Loyola University of Chicago, Stritch School of Medicine, 2005
Offices
1 location · Renal Consultants Medical Group · 9 clinicians in this group
Hospitals listed: 052778 · 552778 · 552853 · Henry Mayo Newhall Hospital · Providence Holy Cross Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ayuste’s office at (661) 254-0193 to ask if they take your plan before you enroll.
California Medical Board record
Licence A99851 · Current
Licensed to practise in California · since 2007 · expires 2027-05-31 · Loyola University of Chicago Stritch School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Nephrology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Henry Mayo Newhall HospitalValencia, CAAcute Care Hospital · Voluntary non-profit - Private · No emergency department · Birthing-friendlyPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.42 (0.65 to 2.18) · 4,172 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.206, Oct 2024 – Sep 2025
- Providence Holy Cross Medical CenterMission Hills, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.404, Oct 2024 – Sep 2025
See every measure and the patient survey for Henry Mayo Newhall Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 3 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 1.42 (0.65 to 2.18) · 4,172 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.206 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.37 (0.37 to 2.37) · 885 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.22 (0.84 to 1.6) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 172.82 (119.12 to 226.52) · 39 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.7 · 122 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.6 · 128 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11 · 285 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.6 · 410 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 214 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 2,687 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,440 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 4,489 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.34 (1.07 to 5.61) · 837 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.32) · 193 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.23 (0.64 to 3.81) · 798 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.74 (0.67 to 18.81) · 197 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.72 (0.6 to 8.85) · 177 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.99 (0.5 to 3.48) · 179 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 6.2 · 66 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.405 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 2.021 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.067 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.091 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.1 · 254 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 586 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 52.4 · 118 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 21.4 · 333 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 628 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12 · 31 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.9 · 225 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.3 (10.8 to 19.1) · 246 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 302 cases | No different | Jan 2024 – Dec 2024 |
What patients said (607 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Providence Holy Cross Medical Center
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 7 the same, 0 worse of 8 measures. Readmissions: 1 better, 7 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.404 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.05 to 1.9) · 1,299 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.93 (0.62 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 168.53 (119.32 to 217.74) · 78 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 42 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.1 · 84 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.7 · 496 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 297 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 316 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 2,960 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0.01 to 0.42) · 5,542 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.06 to 0.45) · 5,701 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.08 (1.02 to 5.14) · 1,284 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.44 (0 to 3.05) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.92 (0.45 to 3.4) · 1,235 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.25 (4.38 to 18.11) · 383 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.75 (2.09 to 9.41) · 353 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.96 (0.48 to 3.44) · 313 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.29 (0 to 0.91) · 4,791 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 166 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.258 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.091 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.947 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.638 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.691 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.4 · 196 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.1 · 948 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -36.2 · 85 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 0.1 · 626 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 10.5 · 315 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17 · 548 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.3 to 8.1) · 30 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.4 (7.2 to 15) · 30 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.7 · 39 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.3 · 104 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.8 to 17.5) · 218 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.3 (0.9 to 1.7) · 119 cases | No different | Jan 2024 – Dec 2024 |
What patients said (439 patients answered, 15% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$438,918
Medicare paid this office $438,918 for 498 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Dialysis services, 4 or more physician visits per month (20 years or older) | 69 | $121,200 | $289 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 217 | $110,079 | $98 |
| Long return visit (40+ min) | 153 | $50,178 | $122 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 110 | $35,930 | $33 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 119 | $33,896 | $41 |
See all 14 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 69 | $121,200 | $289 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 217 | $110,079 | $98 |
| Long return visit (40+ min) | 153 | $50,178 | $122 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 110 | $35,930 | $33 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 119 | $33,896 | $41 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 121 | $19,377 | $142 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 68 | $15,168 | $43 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 36 | $14,344 | $243 |
| Critical care, first 30-74 minutes | 32 | $11,391 | $173 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $6,134 | $65 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 168 | $6,072 | $13 |
| Return visit (30+ min) | 39 | $4,860 | $101 |
| New patient visit (60+ min) | 28 | $4,510 | $161 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 24 | $426 | $18 |
Who their Medicare patients are
498 Original Medicare patients in 2024. Average age 74 · Under 65 16% · 85 and older 19% · Women 48% · Also on Medicaid 62% · Health risk score 4.59. Above the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Diabetes 75% · Chronic kidney disease 75% · Heart failure 63% · Coronary heart disease 55% · Depression 37% · Atrial fibrillation 31% · COPD 30% · Stroke 23% · Dementia 22% · Cancer 17%.
The office billed $1,092,849, Medicare allowed $566,781 and paid $438,918; for 5,177 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 498 | 5,177 | 74 | 4.59 | $1,092,849 | $438,918 |
| 2023 | 460 | 3,698 | 73 | 5.13 | $1,201,091 | $374,152 |
| 2022 | 470 | 3,400 | 74 | 4.30 | $1,090,176 | $363,925 |
| 2021 | 485 | 3,505 | 73 | 4.76 | $1,421,760 | $457,883 |
| 2020 | 406 | 2,346 | 75 | 4.68 | $767,638 | $265,541 |
| 2019 | 431 | 2,815 | 75 | 4.96 | $906,287 | $302,219 |
| 2018 | 444 | 2,649 | 75 | 4.73 | $850,391 | $284,059 |
| 2017 | 393 | 2,713 | 74 | 4.77 | $886,777 | $297,713 |
| 2016 | 396 | 2,914 | 73 | 4.69 | $1,041,925 | $312,491 |
| 2015 | 429 | 2,613 | 74 | 4.85 | $804,014 | $243,125 |
| 2014 | 408 | 2,814 | 74 | 4.43 | $963,868 | $251,409 |
| 2013 | 453 | 2,794 | 74 | 4.35 | $832,099 | $229,089 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 211 | $108,025 | $102 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 80 | $78,023 | $302 |
| Long return visit (40+ min) | 132 | $55,606 | $128 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 187 | $32,044 | $147 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 95 | $21,494 | $43 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 89 | $19,030 | $35 |
| Critical care, first 30-74 minutes | 28 | $15,342 | $180 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 63 | $14,573 | $47 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 25 | $10,885 | $253 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $6,091 | $68 |
| New patient visit (60+ min) | 24 | $4,505 | $188 |
| Return visit (30+ min) | 19 | $3,722 | $103 |
| Complete ultrasound scan behind abdominal cavity | 17 | $1,705 | $100 |
| Complete ultrasound scan of pelvis | 17 | $1,058 | $62 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 41 | $795 | $18 |
2022: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 260 | $126,433 | $88 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 48 | $57,758 | $312 |
| Long return visit (40+ min) | 131 | $56,780 | $143 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 214 | $43,815 | $170 |
| Critical care, first 30-74 minutes | 40 | $17,851 | $186 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 66 | $13,217 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 72 | $11,873 | $62 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 44 | $10,723 | $52 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 17 | $7,266 | $260 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 57 | $7,091 | $36 |
| New patient visit (60+ min) | 19 | $3,547 | $187 |
| Return visit (30+ min) | 15 | $2,990 | $107 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 12 | $214 | $18 |
2021: 17 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 73 | $141,653 | $315 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 273 | $118,880 | $89 |
| Long return visit (40+ min) | 128 | $57,695 | $153 |
| Critical care, first 30-74 minutes | 43 | $36,039 | $188 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 167 | $35,368 | $171 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 54 | $13,728 | $46 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 31 | $11,246 | $262 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 34 | $9,586 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $9,198 | $62 |
| New patient visit (60+ min) | 26 | $4,818 | $185 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 19 | $4,071 | $80 |
| Return visit (30+ min) | 20 | $3,131 | $112 |
| Initial nursing facility care with high level of medical decision making, per day 50 minutes or more | 17 | $2,607 | $145 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 34 | $2,443 | $36 |
| Complete ultrasound scan behind abdominal cavity | 12 | $1,274 | $106 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 48 | $903 | $18 |
| Complete ultrasound scan of pelvis | 12 | $782 | $65 |
2020: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 248 | $109,570 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 197 | $43,152 | $173 |
| Long return visit (40+ min) | 106 | $37,854 | $113 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 12 | $24,880 | $251 |
| Critical care, first 30-74 minutes | 26 | $18,161 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 92 | $14,480 | $63 |
| New patient visit (60+ min) | 24 | $3,592 | $150 |
| Return visit (30+ min) | 27 | $3,038 | $87 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 13 | $2,597 | $81 |
| Initial nursing facility care with high level of medical decision making, per day 50 minutes or more | 16 | $2,294 | $143 |
2019: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 298 | $120,499 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 250 | $53,991 | $172 |
| Long return visit (40+ min) | 84 | $32,679 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 178 | $31,626 | $62 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 21 | $28,286 | $244 |
| Critical care, first 30-74 minutes | 40 | $22,628 | $189 |
| New patient visit (60+ min) | 16 | $2,819 | $176 |
| Return visit (30+ min) | 24 | $2,540 | $79 |
| Complete ultrasound scan behind abdominal cavity | 12 | $1,246 | $104 |
| Complete ultrasound scan of pelvis | 12 | $768 | $64 |
2018: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 302 | $119,969 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 210 | $40,994 | $169 |
| Long return visit (40+ min) | 85 | $31,646 | $119 |
| Critical care, first 30-74 minutes | 60 | $30,743 | $187 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 25 | $23,326 | $243 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 137 | $22,644 | $62 |
| Return visit (30+ min) | 19 | $2,555 | $85 |
| Complete ultrasound scan behind abdominal cavity | 26 | $2,517 | $97 |
| New patient visit (60+ min) | 12 | $2,009 | $167 |
| Complete ultrasound scan of pelvis | 26 | $1,538 | $59 |
| Hemodialysis procedure with physician evaluation | 11 | $679 | $62 |
2017: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 271 | $122,655 | $88 |
| Critical care, first 30-74 minutes | 65 | $48,550 | $188 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 208 | $43,308 | $170 |
| Long return visit (40+ min) | 73 | $28,271 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 125 | $20,647 | $61 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 31 | $15,993 | $228 |
| New patient visit (60+ min) | 13 | $2,169 | $167 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 11 | $2,099 | $191 |
| Return visit (30+ min) | 16 | $1,806 | $79 |
| Hemodialysis procedure with physician evaluation | 17 | $1,407 | $61 |
| Complete ultrasound scan behind abdominal cavity | 13 | $1,360 | $97 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,199 | $92 |
| Hospital discharge day management, 30 minutes or less | 13 | $933 | $62 |
| Complete ultrasound scan of pelvis | 13 | $827 | $59 |
2016: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 232 | $104,161 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 164 | $40,571 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 199 | $39,146 | $170 |
| Critical care, first 30-74 minutes | 63 | $39,013 | $188 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 44 | $38,237 | $232 |
| Long return visit (40+ min) | 54 | $19,071 | $117 |
| Return visit (30+ min) | 51 | $7,483 | $80 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 21 | $5,663 | $195 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $3,824 | $109 |
| Hemodialysis procedure with physician evaluation | 30 | $2,768 | $60 |
2015: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 272 | $69,210 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 169 | $52,880 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 149 | $31,053 | $173 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 43 | $22,081 | $243 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 115 | $15,234 | $116 |
| Critical care, first 30-74 minutes | 35 | $14,958 | $189 |
| Return visit (30+ min) | 70 | $14,136 | $88 |
| Long return visit (40+ min) | 41 | $9,285 | $113 |
| Hemodialysis procedure with physician evaluation | 39 | $3,454 | $61 |
| New patient visit (60+ min) | 12 | $2,135 | $178 |
| New patient visit (45+ min) | 11 | $1,564 | $142 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $992 | $33 |
| Hospital discharge day management, 30 minutes or less | 12 | $875 | $63 |
2014: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 278 | $97,220 | $60 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 56 | $50,965 | $240 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 99 | $24,865 | $87 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 180 | $24,515 | $115 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 80 | $15,097 | $170 |
| Return visit (30+ min) | 71 | $14,995 | $90 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 24 | $6,079 | $203 |
| Hemodialysis procedure with physician evaluation | 37 | $3,964 | $61 |
| Critical care, first 30-74 minutes | 14 | $3,343 | $186 |
| Long return visit (40+ min) | 15 | $2,087 | $123 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 27 | $1,376 | $33 |
| Hospital discharge day management, 30 minutes or less | 12 | $733 | $61 |
2013: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 321 | $95,705 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 177 | $35,112 | $164 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 122 | $31,651 | $84 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 48 | $25,178 | $233 |
| Return visit (30+ min) | 57 | $14,682 | $85 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 87 | $10,334 | $110 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 17 | $3,372 | $198 |
| Critical care, first 30-74 minutes | 14 | $2,862 | $179 |
| Hemodialysis procedure with physician evaluation | 24 | $2,533 | $59 |
| Hospital discharge day management, 30 minutes or less | 38 | $2,439 | $59 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 19 | $1,012 | $32 |
Medicaid work
$36,797 in 2024
Medicaid paid $36,797 for 947 billed services this clinician did in 2024, up to 37 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 252 | $23,341 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 377 | $8,468 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; each additional 20 minutes (List separately in addition to code for primary procedure) | 105 | $2,366 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; first 20 minutes | 172 | $2,097 |
| Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days | 12 | $388 |
| Long return visit (40+ min) | 29 | $137 |
| 2024 | 947 | 6 | 37 | $36,797 |
| 2023 | 1,147 | 6 | 35 | $56,463 |
| 2022 | 782 | 4 | 25 | $35,773 |
| 2021 | 750 | 3 | 23 | $58,366 |
| 2020 | 245 | 2 | 15 | $10,373 |
| 2019 | 77 | 2 | 15 | $1,432 |
| 2018 | 96 | 1 | 18 | $2,115 |
See the largest Medicaid services in earlier years
2023
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 178 | $26,752 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 560 | $18,134 |
| 1ST HOSP IP/OBS HIGH 75 | 103 | $7,644 |
| Long return visit (40+ min) | 80 | $2,287 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; each additional 20 minutes (List separately in addition to code for primary procedure) | 87 | $864 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; first 20 minutes | 139 | $783 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 638 | $18,574 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 64 | $13,544 |
| 1ST HOSP IP/OBS HIGH 75 | 39 | $2,529 |
| Long return visit (40+ min) | 41 | $1,126 |
2021
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 189 | $37,357 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 535 | $19,208 |
| 1ST HOSP IP/OBS HIGH 75 | 26 | $1,802 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 231 | $9,521 |
| 1ST HOSP IP/OBS HIGH 75 | 14 | $852 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 63 | $960 |
| 1ST HOSP IP/OBS HIGH 75 | 14 | $471 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 96 | $2,115 |
Drugs they prescribed that Part D paid
$573,690
Pharmacies billed $573,690 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
2,440 generic and 469 brand-name prescriptions · $573,690 in drug cost · 46 antibiotic prescriptions to 32 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Veltassa | 79 | $87,229 | $1,104 |
| Kerendia | 103 | $83,623 | $812 |
| Lokelma | 79 | $63,447 | $803 |
| Farxiga | 33 | $32,568 | $987 |
| Auryxia | 11 | $20,936 | $1,903 |
See all 55 drugs
| Veltassa | 79 | $87,229 | $1,104 |
| Kerendia | 103 | $83,623 | $812 |
| Lokelma | 79 | $63,447 | $803 |
| Farxiga | 33 | $32,568 | $987 |
| Auryxia | 11 | $20,936 | $1,903 |
| Jardiance | 24 | $19,719 | $822 |
| Prolia | 11 | $18,521 | $1,684 |
| Entresto | 13 | $15,289 | $1,176 |
| Paricalcitol | 99 | $12,381 | $125 |
| Cinacalcet | 21 | $10,294 | $490 |
| Sevelamer Carbonate | 40 | $6,462 | $162 |
| Diflorasone Diacetate | 12 | $6,161 | $513 |
| Prosol | 24 | $3,876 | $161 |
| Nifedipine Er | 108 | $3,773 | $35 |
| Hydralazine | 266 | $3,066 | $12 |
| Valsartan | 90 | $2,791 | $31 |
| Tamsulosin | 166 | $2,679 | $16 |
| Clonidine | 22 | $1,638 | $74 |
| Calcium Acetate | 19 | $1,606 | $85 |
| Potassium Citrate Er | 15 | $1,519 | $101 |
| Losartan | 91 | $1,119 | $12 |
| Famotidine | 19 | $1,065 | $56 |
| Allopurinol | 118 | $950 | $8 |
| Atorvastatin | 96 | $923 | $10 |
| Amlodipine Besylate | 132 | $893 | $7 |
| Labetalol | 32 | $805 | $25 |
| Bumetanide | 23 | $744 | $32 |
| Finasteride | 82 | $591 | $7 |
| Furosemide | 138 | $568 | $4 |
| Spironolactone | 45 | $528 | $12 |
| Metoprolol | 31 | $460 | $15 |
| Clonidine | 29 | $449 | $15 |
| Calcitriol | 28 | $440 | $16 |
| Doxazosin Mesylate | 24 | $411 | $17 |
| Carvedilol | 54 | $383 | $7 |
| Chlorthalidone | 20 | $374 | $19 |
| Lisinopril | 54 | $345 | $6 |
| Benazepril | 44 | $319 | $7 |
| Levothyroxine | 25 | $273 | $11 |
| Amiloride | 20 | $240 | $12 |
| Vitamin D2 | 18 | $238 | $13 |
| Prednisone | 26 | $192 | $7 |
| Glipizide Er | 21 | $186 | $9 |
| Pantoprazole | 36 | $156 | $4 |
| Gabapentin | 11 | $146 | $13 |
| Olmesartan Medoxomil | 17 | $114 | $7 |
| Oxybutynin Chloride Er | 11 | $101 | $9 |
| Rosuvastatin | 18 | $101 | $6 |
| Glipizide | 15 | $100 | $7 |
| Alendronate | 17 | $92 | $5 |
| Metoprolol | 24 | $91 | $4 |
| Potassium Chloride | 11 | $80 | $7 |
| Atenolol | 13 | $55 | $4 |
| Simvastatin | 15 | $54 | $4 |
| Cephalexin | 25 | $53 | $2 |
Year by year
| 2024 | 2,921 | 339 | None | 16% | $573,690 |
| 2023 | 3,041 | 306 | None | 18% | $789,425 |
| 2022 | 2,789 | 271 | 0% (0) | 16% | $432,518 |
| 2021 | 2,293 | 241 | None | 19% | $448,454 |
| 2020 | 1,609 | 196 | None | None | $312,599 |
| 2019 | 1,499 | 177 | None | 21% | $365,340 |
| 2018 | 1,482 | 161 | None | 21% | $305,808 |
| 2017 | 1,660 | 151 | None | None | $248,223 |
| 2016 | 1,541 | 134 | None | None | $168,015 |
| 2015 | 1,360 | 136 | 1% (15) | None | $147,421 |
| 2014 | 1,239 | 138 | None | None | $106,871 |
| 2013 | 1,415 | 162 | 1% (14) | None | $104,175 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 55 drugs
| Kerendia | 163 | $132,903 | $815 |
| Veltassa | 79 | $99,890 | $1,264 |
| Lokelma | 83 | $62,304 | $751 |
| Farxiga | 29 | $31,868 | $1,099 |
| Entresto | 14 | $26,198 | $1,871 |
| Lanthanum Carbonate | 18 | $19,986 | $1,110 |
| Paricalcitol | 87 | $17,017 | $196 |
| Sevelamer Carbonate | 34 | $16,030 | $471 |
| Crotan | 11 | $15,833 | $1,439 |
| Cinacalcet | 18 | $10,753 | $597 |
| Tamsulosin | 186 | $7,930 | $43 |
| Nifedipine Er | 60 | $5,640 | $94 |
| Hydralazine | 233 | $5,517 | $24 |
| Retacrit | 13 | $5,331 | $410 |
| Clonidine | 32 | $3,964 | $124 |
| Febuxostat | 12 | $3,430 | $286 |
| Valsartan | 59 | $3,157 | $54 |
| Losartan | 127 | $2,304 | $18 |
| Potassium Citrate Er | 19 | $2,052 | $108 |
| Allopurinol | 116 | $1,970 | $17 |
| Calcium Acetate | 23 | $1,928 | $84 |
| Furosemide | 236 | $1,800 | $8 |
| Mycophenolate Mofetil | 11 | $1,669 | $152 |
| Finasteride | 71 | $1,619 | $23 |
| Labetalol | 24 | $1,419 | $59 |
| Amlodipine Besylate | 117 | $1,346 | $12 |
| Bumetanide | 25 | $1,338 | $54 |
| Rosuvastatin | 15 | $1,301 | $87 |
| Atorvastatin | 81 | $1,187 | $15 |
| Doxazosin Mesylate | 26 | $858 | $33 |
| Levothyroxine | 35 | $849 | $24 |
| Carvedilol | 39 | $798 | $20 |
| Metoprolol | 21 | $730 | $35 |
| Omega-3 Acid Ethyl Esters | 13 | $691 | $53 |
| Chlorthalidone | 23 | $675 | $29 |
| Lisinopril | 50 | $643 | $13 |
| Spironolactone | 43 | $591 | $14 |
| Olmesartan Medoxomil | 28 | $589 | $21 |
| Pantoprazole | 29 | $534 | $18 |
| Metoprolol | 36 | $486 | $14 |
| Calcitriol | 14 | $454 | $32 |
| Benazepril | 35 | $419 | $12 |
| Gabapentin | 24 | $410 | $17 |
| Prednisone | 45 | $406 | $9 |
| Clonidine | 14 | $344 | $25 |
| Glipizide Er | 12 | $310 | $26 |
| Famotidine | 14 | $310 | $22 |
| Amiloride | 19 | $253 | $13 |
| Alendronate | 15 | $246 | $16 |
| Simvastatin | 19 | $213 | $11 |
| Cephalexin | 51 | $208 | $4 |
| Atenolol | 12 | $127 | $11 |
| Glipizide | 13 | $113 | $9 |
| Irbesartan | 14 | $78 | $6 |
| Amoxicillin-Clavulanate Potass | 13 | $61 | $5 |
2022: 56 drugs
| Veltassa | 75 | $86,582 | $1,154 |
| Lokelma | 54 | $34,817 | $645 |
| Kerendia | 50 | $34,477 | $690 |
| Farxiga | 26 | $26,306 | $1,012 |
| Jardiance | 12 | $14,626 | $1,219 |
| Paricalcitol | 57 | $11,667 | $205 |
| Cinacalcet | 27 | $10,930 | $405 |
| Sevelamer Carbonate | 41 | $10,602 | $259 |
| Retacrit | 17 | $7,775 | $457 |
| Epogen | 11 | $6,666 | $606 |
| Vascepa | 12 | $6,568 | $547 |
| Potassium Citrate Er | 47 | $4,295 | $91 |
| Nifedipine Er | 47 | $4,274 | $91 |
| Tamsulosin | 152 | $3,804 | $25 |
| Hydralazine | 194 | $3,531 | $18 |
| Allopurinol | 130 | $2,442 | $19 |
| Labetalol | 41 | $2,186 | $53 |
| Rosuvastatin | 29 | $2,003 | $69 |
| Clonidine | 15 | $1,518 | $101 |
| Losartan | 125 | $1,414 | $11 |
| Valsartan | 44 | $1,397 | $32 |
| Calcium Acetate | 21 | $1,346 | $64 |
| Furosemide | 197 | $1,154 | $6 |
| Atorvastatin | 89 | $1,107 | $12 |
| Levothyroxine | 49 | $1,064 | $22 |
| Amlodipine Besylate | 96 | $1,014 | $11 |
| Doxazosin Mesylate | 42 | $954 | $23 |
| Finasteride | 68 | $888 | $13 |
| Bumetanide | 19 | $839 | $44 |
| Pentoxifylline | 19 | $755 | $40 |
| Carvedilol | 52 | $712 | $14 |
| Spironolactone | 46 | $706 | $15 |
| Chlorthalidone | 25 | $675 | $27 |
| Olmesartan Medoxomil | 21 | $617 | $29 |
| Metoprolol | 21 | $606 | $29 |
| Calcitriol | 13 | $487 | $37 |
| Pantoprazole | 35 | $419 | $12 |
| Ondansetron | 11 | $414 | $38 |
| Prednisone | 26 | $304 | $12 |
| Benazepril | 32 | $250 | $8 |
| Simvastatin | 30 | $211 | $7 |
| Clopidogrel | 11 | $193 | $18 |
| Metoprolol | 34 | $190 | $6 |
| Lisinopril | 28 | $173 | $6 |
| Metoclopramide | 14 | $148 | $11 |
| Gabapentin | 20 | $147 | $7 |
| Fluticasone Propionate | 13 | $143 | $11 |
| Alendronate | 13 | $141 | $11 |
| Vitamin D2 | 12 | $128 | $11 |
| Cephalexin | 37 | $91 | $2 |
| Amoxicillin-Clavulanate Potass | 15 | $86 | $6 |
| Glipizide | 14 | $71 | $5 |
| Ciprofloxacin | 16 | $65 | $4 |
| Metformin | 11 | $27 | $2 |
| Easy-Touch Insulin | 18 | $24 | $1 |
| Insulin | 16 | $23 | $1 |
2021: 50 drugs
| Veltassa | 121 | $118,456 | $979 |
| Samsca | 14 | $61,339 | $4,381 |
| Lokelma | 45 | $29,854 | $663 |
| Cinacalcet | 39 | $29,073 | $745 |
| Aranesp | 16 | $25,138 | $1,571 |
| Retacrit | 33 | $21,893 | $663 |
| Procrit | 21 | $14,060 | $670 |
| Paricalcitol | 51 | $11,433 | $224 |
| Potassium Citrate Er | 58 | $5,948 | $103 |
| Febuxostat | 24 | $5,135 | $214 |
| Nifedipine Er | 39 | $3,085 | $79 |
| Hydralazine | 153 | $2,914 | $19 |
| Tamsulosin | 114 | $2,842 | $25 |
| Labetalol | 37 | $2,738 | $74 |
| Allopurinol | 81 | $1,732 | $21 |
| Rosuvastatin | 14 | $1,471 | $105 |
| Furosemide | 163 | $1,274 | $8 |
| Calcitriol | 29 | $1,269 | $44 |
| Sevelamer Carbonate | 13 | $1,239 | $95 |
| Losartan | 75 | $1,228 | $16 |
| Doxazosin Mesylate | 41 | $1,096 | $27 |
| Levothyroxine | 32 | $871 | $27 |
| Olmesartan Medoxomil | 19 | $854 | $45 |
| Spironolactone | 41 | $836 | $20 |
| Finasteride | 52 | $776 | $15 |
| Atorvastatin | 57 | $757 | $13 |
| Valsartan | 27 | $680 | $25 |
| Chlorthalidone | 16 | $667 | $42 |
| Amlodipine Besylate | 87 | $654 | $8 |
| Metoprolol | 22 | $640 | $29 |
| Albuterol Sulfate Hfa | 11 | $521 | $47 |
| Tacrolimus | 13 | $488 | $38 |
| Bumetanide | 14 | $389 | $28 |
| Carvedilol | 37 | $373 | $10 |
| Irbesartan | 12 | $373 | $31 |
| Omeprazole | 15 | $329 | $22 |
| Pantoprazole | 24 | $304 | $13 |
| Benazepril | 32 | $277 | $9 |
| Lisinopril | 38 | $260 | $7 |
| Prednisone | 16 | $221 | $14 |
| Gabapentin | 12 | $143 | $12 |
| Hydrochlorothiazide | 12 | $131 | $11 |
| Alendronate | 17 | $121 | $7 |
| Metoprolol | 15 | $108 | $7 |
| Simvastatin | 18 | $93 | $5 |
| Amoxicillin-Clavulanate Potass | 17 | $92 | $5 |
| Ciprofloxacin | 22 | $85 | $4 |
| Metformin | 14 | $58 | $4 |
| Cephalexin | 23 | $55 | $2 |
| Insulin | 32 | $43 | $1 |
2020: 39 drugs
| Veltassa | 90 | $90,269 | $1,003 |
| Samsca | 12 | $47,820 | $3,985 |
| Rayaldee | 20 | $22,834 | $1,142 |
| Aranesp | 13 | $15,372 | $1,182 |
| Retacrit | 33 | $14,566 | $441 |
| Procrit | 15 | $13,138 | $876 |
| Lokelma | 18 | $12,764 | $709 |
| Vascepa | 28 | $10,081 | $360 |
| Cinacalcet | 17 | $9,338 | $549 |
| Febuxostat | 18 | $7,245 | $403 |
| Paricalcitol | 35 | $6,223 | $178 |
| Eliquis | 11 | $5,443 | $495 |
| Potassium Citrate Er | 47 | $5,159 | $110 |
| Tamsulosin | 102 | $2,635 | $26 |
| Hydralazine | 102 | $2,260 | $22 |
| Olmesartan Medoxomil | 27 | $1,859 | $69 |
| Labetalol | 33 | $1,699 | $51 |
| Doxazosin Mesylate | 56 | $1,439 | $26 |
| Bumetanide | 23 | $1,352 | $59 |
| Nifedipine Er | 12 | $1,347 | $112 |
| Allopurinol | 76 | $1,288 | $17 |
| Atorvastatin | 47 | $862 | $18 |
| Finasteride | 39 | $861 | $22 |
| Furosemide | 104 | $648 | $6 |
| Calcitriol | 16 | $586 | $37 |
| Spironolactone | 57 | $582 | $10 |
| Levothyroxine | 18 | $566 | $31 |
| Losartan | 43 | $564 | $13 |
| Amlodipine Besylate | 56 | $418 | $7 |
| Carvedilol | 36 | $359 | $10 |
| Valsartan | 12 | $354 | $30 |
| Benazepril | 25 | $222 | $9 |
| Hydrochlorothiazide | 17 | $167 | $10 |
| Prednisone | 12 | $162 | $13 |
| Lisinopril | 35 | $159 | $5 |
| Amoxicillin-Clavulanate Potass | 19 | $102 | $5 |
| Alendronate | 16 | $94 | $6 |
| Omeprazole | 14 | $88 | $6 |
| Cephalexin | 23 | $58 | $3 |
2019: 34 drugs
| Samsca | 16 | $90,720 | $5,670 |
| Veltassa | 72 | $67,465 | $937 |
| Procrit | 20 | $13,985 | $699 |
| Paricalcitol | 42 | $12,397 | $295 |
| Uloric | 13 | $7,086 | $545 |
| Cyclosporine | 18 | $4,753 | $264 |
| Vascepa | 14 | $4,138 | $296 |
| Potassium Citrate Er | 32 | $3,778 | $118 |
| Tamsulosin | 121 | $2,827 | $23 |
| Hydralazine | 113 | $2,563 | $23 |
| Allopurinol | 99 | $2,065 | $21 |
| Bumetanide | 27 | $1,234 | $46 |
| Atorvastatin | 38 | $1,094 | $29 |
| Finasteride | 43 | $1,026 | $24 |
| Doxazosin Mesylate | 37 | $897 | $24 |
| Labetalol | 16 | $798 | $50 |
| Furosemide | 101 | $627 | $6 |
| Spironolactone | 42 | $597 | $14 |
| Levothyroxine | 23 | $566 | $25 |
| Calcitriol | 15 | $507 | $34 |
| Amlodipine Besylate | 52 | $503 | $10 |
| Losartan | 35 | $422 | $12 |
| Clonidine | 11 | $406 | $37 |
| Olmesartan Medoxomil | 13 | $404 | $31 |
| Amiloride | 15 | $377 | $25 |
| Benazepril | 48 | $355 | $7 |
| Simvastatin | 16 | $340 | $21 |
| Alendronate | 30 | $297 | $10 |
| Lisinopril | 27 | $217 | $8 |
| Carvedilol | 20 | $204 | $10 |
| Ciprofloxacin | 16 | $99 | $6 |
| Cephalexin | 22 | $77 | $3 |
| Amoxicillin-Clavulanate Potass | 11 | $70 | $6 |
| Hydrochlorothiazide | 19 | $62 | $3 |
2018: 33 drugs
| Samsca | 11 | $58,440 | $5,313 |
| Veltassa | 67 | $57,063 | $852 |
| Procrit | 35 | $26,671 | $762 |
| Paricalcitol | 42 | $18,622 | $443 |
| Uloric | 23 | $16,057 | $698 |
| Cyclosporine | 17 | $4,316 | $254 |
| Potassium Citrate Er | 30 | $3,823 | $127 |
| Tamsulosin | 89 | $2,789 | $31 |
| Allopurinol | 96 | $2,324 | $24 |
| Hydralazine | 101 | $2,296 | $23 |
| Atorvastatin | 42 | $1,050 | $25 |
| Spironolactone | 57 | $1,009 | $18 |
| Bumetanide | 11 | $930 | $85 |
| Finasteride | 43 | $836 | $19 |
| Metoprolol | 23 | $829 | $36 |
| Labetalol | 13 | $740 | $57 |
| Furosemide | 124 | $686 | $6 |
| Losartan | 58 | $572 | $10 |
| Doxazosin Mesylate | 12 | $499 | $42 |
| Calcitriol | 19 | $435 | $23 |
| Amlodipine Besylate | 49 | $427 | $9 |
| Alendronate | 43 | $422 | $10 |
| Levothyroxine | 16 | $400 | $25 |
| Polyethylene Glycol 3350 | 20 | $334 | $17 |
| Benazepril | 29 | $248 | $9 |
| Carvedilol | 24 | $219 | $9 |
| Lisinopril | 30 | $217 | $7 |
| Pantoprazole | 20 | $191 | $10 |
| Simvastatin | 19 | $145 | $8 |
| Omeprazole | 20 | $128 | $6 |
| Amoxicillin-Clavulanate Potass | 16 | $107 | $7 |
| Ciprofloxacin | 17 | $65 | $4 |
| Hydrochlorothiazide | 19 | $46 | $2 |
2017: 39 drugs
| Samsca | 13 | $72,630 | $5,587 |
| Veltassa | 54 | $38,846 | $719 |
| Paricalcitol | 59 | $21,307 | $361 |
| Uloric | 39 | $14,641 | $375 |
| Procrit | 20 | $12,682 | $634 |
| Potassium Citrate Er | 33 | $4,237 | $128 |
| Cyclosporine | 14 | $4,232 | $302 |
| Tamsulosin | 83 | $2,792 | $34 |
| Allopurinol | 114 | $2,413 | $21 |
| Hydralazine | 100 | $2,343 | $23 |
| Labetalol | 23 | $2,290 | $100 |
| Atorvastatin | 50 | $1,099 | $22 |
| Finasteride | 47 | $894 | $19 |
| Spironolactone | 59 | $853 | $14 |
| Amlodipine Besylate | 91 | $781 | $9 |
| Bumetanide | 12 | $754 | $63 |
| Levothyroxine | 34 | $668 | $20 |
| Valsartan | 18 | $664 | $37 |
| Calcitriol | 15 | $623 | $42 |
| Furosemide | 112 | $570 | $5 |
| Metoprolol | 22 | $539 | $24 |
| Losartan | 53 | $467 | $9 |
| Nifedipine Er | 11 | $407 | $37 |
| Doxazosin Mesylate | 11 | $386 | $35 |
| Benazepril | 46 | $380 | $8 |
| Carvedilol | 51 | $346 | $7 |
| Pantoprazole | 25 | $310 | $12 |
| Polyethylene Glycol 3350 | 14 | $256 | $18 |
| Alendronate | 36 | $227 | $6 |
| Simvastatin | 22 | $220 | $10 |
| Terazosin | 11 | $189 | $17 |
| Prednisone | 11 | $150 | $14 |
| Amoxicillin-Clavulanate Potass | 17 | $104 | $6 |
| Lisinopril | 24 | $102 | $4 |
| Ciprofloxacin | 21 | $99 | $5 |
| Omeprazole | 13 | $77 | $6 |
| Gabapentin | 13 | $76 | $6 |
| Atenolol | 13 | $71 | $5 |
| Cephalexin | 18 | $62 | $3 |
2016: 36 drugs
| Procrit | 25 | $18,860 | $754 |
| Valganciclovir | 12 | $17,017 | $1,418 |
| Paricalcitol | 50 | $13,642 | $273 |
| Cellcept | 11 | $9,721 | $884 |
| Uloric | 24 | $9,121 | $380 |
| Veltassa | 14 | $8,648 | $618 |
| Tamsulosin | 102 | $3,369 | $33 |
| Potassium Citrate Er | 17 | $2,604 | $153 |
| Allopurinol | 108 | $2,163 | $20 |
| Calcitriol | 46 | $2,150 | $47 |
| Hydralazine | 87 | $1,893 | $22 |
| Labetalol | 36 | $1,707 | $47 |
| Bumetanide | 13 | $1,511 | $116 |
| Valsartan | 11 | $1,123 | $102 |
| Amlodipine Besylate | 88 | $757 | $9 |
| Furosemide | 114 | $701 | $6 |
| Atorvastatin | 40 | $685 | $17 |
| Metoprolol | 20 | $646 | $32 |
| Spironolactone | 42 | $566 | $13 |
| Finasteride | 33 | $550 | $17 |
| Levothyroxine | 24 | $526 | $22 |
| Benazepril | 61 | $519 | $9 |
| Doxazosin Mesylate | 12 | $431 | $36 |
| Carvedilol | 60 | $340 | $6 |
| Losartan | 27 | $298 | $11 |
| Alendronate | 28 | $220 | $8 |
| Amiloride | 16 | $219 | $14 |
| Pantoprazole | 24 | $196 | $8 |
| Diltiazem 24hr Er | 13 | $140 | $11 |
| Terazosin | 12 | $137 | $11 |
| Clonidine | 20 | $120 | $6 |
| Metoprolol | 16 | $98 | $6 |
| Ciprofloxacin | 17 | $97 | $6 |
| Lisinopril | 16 | $64 | $4 |
| Cephalexin | 12 | $45 | $4 |
| Glipizide | 11 | $37 | $3 |
2015: 35 drugs
| Procrit | 35 | $30,438 | $870 |
| Renvela | 14 | $22,653 | $1,618 |
| Uloric | 40 | $9,999 | $250 |
| Paricalcitol | 25 | $6,359 | $254 |
| Colcrys | 15 | $5,050 | $337 |
| Hydralazine | 108 | $1,939 | $18 |
| Calcitriol | 35 | $1,726 | $49 |
| Tamsulosin | 49 | $1,309 | $27 |
| Sodium Polystyrene Sulfonate | 11 | $1,241 | $113 |
| Labetalol | 24 | $1,057 | $44 |
| Allopurinol | 60 | $1,005 | $17 |
| Amlodipine Besylate | 88 | $896 | $10 |
| Nifedipine Er | 15 | $737 | $49 |
| Furosemide | 118 | $655 | $6 |
| Doxazosin Mesylate | 15 | $627 | $42 |
| Levothyroxine | 27 | $624 | $23 |
| Benazepril | 61 | $603 | $10 |
| Atorvastatin | 21 | $450 | $21 |
| Potassium Chloride | 12 | $404 | $34 |
| Losartan | 40 | $380 | $9 |
| Carvedilol | 39 | $363 | $9 |
| Finasteride | 16 | $304 | $19 |
| Spironolactone | 32 | $249 | $8 |
| Afeditab Cr | 11 | $231 | $21 |
| Terazosin | 16 | $230 | $14 |
| Clonidine | 35 | $188 | $5 |
| Zolpidem | 14 | $169 | $12 |
| Alendronate | 15 | $161 | $11 |
| Metoprolol | 25 | $147 | $6 |
| Prednisone | 16 | $114 | $7 |
| Lisinopril | 18 | $107 | $6 |
| Lovastatin | 11 | $83 | $8 |
| Pantoprazole | 11 | $72 | $7 |
| Hydrochlorothiazide | 11 | $58 | $5 |
| Ciprofloxacin | 11 | $53 | $5 |
2014: 30 drugs
| Procrit | 34 | $35,831 | $1,054 |
| Paricalcitol | 32 | $12,827 | $401 |
| Renvela | 13 | $10,606 | $816 |
| Uloric | 36 | $7,483 | $208 |
| Colcrys | 12 | $3,361 | $280 |
| Nifedipine Er | 29 | $2,058 | $71 |
| Hydralazine | 93 | $1,840 | $20 |
| Calcium Acetate | 13 | $1,188 | $91 |
| Amlodipine Besylate | 96 | $922 | $10 |
| Labetalol | 22 | $846 | $38 |
| Losartan | 54 | $799 | $15 |
| Furosemide | 140 | $672 | $5 |
| Benazepril | 73 | $629 | $9 |
| Doxazosin Mesylate | 14 | $564 | $40 |
| Allopurinol | 70 | $558 | $8 |
| Proair Hfa | 11 | $542 | $49 |
| Tamsulosin | 31 | $535 | $17 |
| Metolazone | 11 | $311 | $28 |
| Levothyroxine | 21 | $301 | $14 |
| Afeditab Cr | 11 | $234 | $21 |
| Carvedilol | 27 | $216 | $8 |
| Terazosin | 14 | $212 | $15 |
| Metoprolol | 35 | $161 | $5 |
| Lisinopril | 18 | $143 | $8 |
| Simvastatin | 16 | $116 | $7 |
| Spironolactone | 15 | $104 | $7 |
| Hydrochlorothiazide | 16 | $102 | $6 |
| Omeprazole | 11 | $92 | $8 |
| Zolpidem | 13 | $85 | $7 |
| Lovastatin | 11 | $80 | $7 |
2013: 32 drugs
| Procrit | 50 | $32,451 | $649 |
| Zemplar | 30 | $12,948 | $432 |
| Colcrys | 13 | $3,986 | $307 |
| Diovan | 13 | $3,708 | $285 |
| Hydralazine | 125 | $3,105 | $25 |
| Nifedipine Er | 40 | $2,329 | $58 |
| Uloric | 11 | $2,216 | $201 |
| Sodium Polystyrene Sulfonate | 11 | $1,088 | $99 |
| Benazepril | 113 | $958 | $8 |
| Losartan | 66 | $933 | $14 |
| Amlodipine Besylate | 107 | $864 | $8 |
| Labetalol | 13 | $840 | $65 |
| Calcitriol | 18 | $815 | $45 |
| Furosemide | 103 | $474 | $5 |
| Spironolactone | 47 | $457 | $10 |
| Tamsulosin | 31 | $456 | $15 |
| Metolazone | 19 | $444 | $23 |
| Allopurinol | 65 | $426 | $7 |
| Metoprolol | 54 | $380 | $7 |
| Lovastatin | 16 | $355 | $22 |
| Isosorbide Mononitrate Er | 26 | $355 | $14 |
| Afeditab Cr | 11 | $322 | $29 |
| Bumetanide | 14 | $276 | $20 |
| Omeprazole | 20 | $273 | $14 |
| Hydrocodone-Acetaminophen | 11 | $247 | $22 |
| Lisinopril | 24 | $196 | $8 |
| Zolpidem | 26 | $171 | $7 |
| Doxazosin Mesylate | 11 | $135 | $12 |
| Simvastatin | 12 | $132 | $11 |
| Temazepam | 12 | $103 | $9 |
| Hydrochlorothiazide | 18 | $63 | $4 |
| Atenolol | 11 | $49 | $4 |
Money from drug and device companies
$1,480 in 2025
| 2025 | 17 | 78 | None | $1,480 |
| 2024 | 15 | 60 | None | $1,391 |
| 2023 | 12 | 60 | None | $1,234 |
| 2022 | 9 | 37 | None | $661 |
| 2021 | 4 | 5 | None | $193 |
| 2020 | 6 | 8 | None | $160 |
| 2019 | 9 | 23 | None | $365 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Krystexxa | $309 | 18 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $148 | 5 payments
|
| Novartis Pharmaceuticals | Leqvio | $144 | 9 payments
|
| Otsuka America Pharmaceutical | Jynarque | $143 | 6 payments
|
| Calliditas Therapeutics US | Tarpeyo | $105 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $98 | 4 payments
|
See all 71 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-17 | Lokelma | $30 |
| Otsuka America Pharmaceutical | Meals · 2025-12-17 | Voyxact | $32 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-13 | Jardiance | $21 |
| Calliditas Therapeutics US | Meals · 2025-11-11 | Tarpeyo | $37 |
| Aurinia Pharma U.S. | Meals · 2025-11-07 | Lupkynis | $24 |
| OPKO Pharmaceuticals | Meals · 2025-10-23 | Rayaldee | $22 |
| GlaxoSmithKline | Meals · 2025-10-21 | Benlysta | $18 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-21 | Livtencity | $32 |
| Amgen | Education · 2025-10-21 | Krystexxa | $1 |
| Amgen | Meals · 2025-10-21 | Krystexxa | $15 |
| Amgen | Meals · 2025-10-16 | Tavneos | $23 |
| Travere Therapeutics | Meals · 2025-10-14 | None | $24 |
| Novartis Pharmaceuticals | Meals · 2025-09-30 | None | $7 |
| Novartis Pharmaceuticals | Meals · 2025-09-30 | None | $28 |
| Otsuka America Pharmaceutical | Meals · 2025-09-23 | Jynarque | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-02 | Lokelma | $14 |
| Amgen | Meals · 2025-08-26 | Krystexxa | $19 |
| GlaxoSmithKline | Meals · 2025-08-20 | Shingrix | $17 |
| Amgen | Meals · 2025-08-19 | Krystexxa | $29 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-14 | Jardiance | $20 |
| Amgen | Meals · 2025-08-14 | Tavneos | $4 |
| Exact Sciences | Meals · 2025-08-12 | The Cologuard Plus Collection Kit | $19 |
| Amgen | Meals · 2025-08-07 | Tavneos | $26 |
| Novartis Pharmaceuticals | Meals · 2025-07-29 | Leqvio | $18 |
| Akebia Therapeutics | Meals · 2025-07-24 | Vafseo | $27 |
| Otsuka America Pharmaceutical | Meals · 2025-07-22 | Jynarque | $21 |
| Novo Nordisk | Meals · 2025-07-16 | Ozempic | $21 |
| Amgen | Meals · 2025-07-10 | Krystexxa | $27 |
| GlaxoSmithKline | Meals · 2025-07-01 | Benlysta | $21 |
| Amgen | Meals · 2025-06-24 | Krystexxa | $13 |
| Aurinia Pharma U.S. | Meals · 2025-06-19 | Lupkynis | $19 |
| Otsuka America Pharmaceutical | Meals · 2025-06-17 | Jynarque | $20 |
| Novartis Pharmaceuticals | Meals · 2025-06-10 | None | $29 |
| Novartis Pharmaceuticals | Meals · 2025-06-10 | None | $4 |
| Ardelyx | Meals · 2025-06-05 | Ibsrela | $25 |
| Amgen | Meals · 2025-06-03 | Krystexxa | $13 |
| Calliditas Therapeutics US | Meals · 2025-06-03 | Tarpeyo | $21 |
| Novo Nordisk | Meals · 2025-05-27 | Ozempic | $18 |
| Novo Nordisk | Education · 2025-05-27 | Ozempic | $16 |
| GlaxoSmithKline | Meals · 2025-05-21 | Benlysta | $21 |
| Amgen | Meals · 2025-05-20 | Krystexxa | $25 |
| Travere Therapeutics | Meals · 2025-05-13 | None | $12 |
| Amgen | Meals · 2025-05-08 | Tavneos | $31 |
| Novartis Pharmaceuticals | Meals · 2025-05-01 | None | $11 |
| Novartis Pharmaceuticals | Meals · 2025-05-01 | None | $15 |
| Calliditas Therapeutics US | Meals · 2025-04-29 | Tarpeyo | $29 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-04-03 | Kerendia | $20 |
| Novo Nordisk | Meals · 2025-04-01 | Ozempic | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-26 | Farxiga | $23 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-20 | Jardiance | $23 |
| Novartis Pharmaceuticals | Meals · 2025-03-18 | None | $24 |
| Novartis Pharmaceuticals | Meals · 2025-03-18 | None | $8 |
| Ardelyx | Meals · 2025-03-13 | Ibsrela | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-11 | Farxiga | $14 |
| Akebia Therapeutics | Meals · 2025-03-06 | Vafseo | $25 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-25 | Jardiance | $34 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-25 | Kerendia | $14 |
| Amgen | Meals · 2025-02-20 | Tavneos | $8 |
| Aurinia Pharma U.S. | Meals · 2025-02-20 | Lupkynis | $28 |
| Amgen | Meals · 2025-02-18 | Krystexxa | $28 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-13 | Kerendia | $22 |
| Otsuka America Pharmaceutical | Meals · 2025-02-06 | Jynarque | $30 |
| GlaxoSmithKline | Meals · 2025-02-04 | Benlysta | $19 |
| Amgen | Meals · 2025-01-23 | Krystexxa | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-21 | Farxiga | $66 |
| Otsuka America Pharmaceutical | Meals · 2025-01-21 | Jynarque | $20 |
| Vifor Pharma | Meals · 2025-01-16 | Veltassa | $29 |
| Calliditas Therapeutics US | Meals · 2025-01-14 | Tarpeyo | $17 |
| Amgen | Meals · 2025-01-10 | Krystexxa | $10 |
| Amgen | Meals · 2025-01-09 | Krystexxa | $8 |
| Amgen | Meals · 2025-01-07 | Krystexxa | $11 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,391
| Amgen | Krystexxa | $405 | 17 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $191 | 8 payments
|
| Aurinia Pharma U.S. | Lupkynis | $112 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $111 | 4 payments
|
| GlaxoSmithKline | Jesduvroq | $93 | 3 payments
|
| Novartis Pharmaceuticals | Fabhalta | $90 | 3 payments
|
| Otsuka America Pharmaceutical | Jynarque | $90 | 4 payments
|
| Akebia Therapeutics | Auryxia | $81 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $60 | 3 payments
|
| Mallinckrodt Hospital Products | Terlivaz | $49 | 2 payments
|
| Calliditas Therapeutics US | Tarpeyo | $39 | 2 payments
|
| OPKO Pharmaceuticals | Rayaldee | $20 | 1 payment
|
| Vifor Pharma | Veltassa | $20 | 1 payment
|
| Lilly USA | Mounjaro | $18 | 1 payment
|
| Travere Therapeutics | None | $12 | 1 payment
|
2023: $1,234
| GlaxoSmithKline | Benlysta | $346 | 15 payments
|
| Horizon Therapeutics plc | Krystexxa | $195 | 15 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $175 | 8 payments
|
| Aurinia Pharma U.S. | Lupkynis | $142 | 7 payments
|
| Otsuka America Pharmaceutical | Jynarque | $131 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $56 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $55 | 2 payments
|
| Calliditas Therapeutics US | Tarpeyo | $42 | 2 payments
|
| Vifor Pharma | Veltassa | $25 | 1 payment
|
| Travere Therapeutics | None | $25 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $24 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $20 | 1 payment
|
2022: $661
| AstraZeneca Pharmaceuticals LP | Lokelma | $262 | 11 payments
|
| Horizon Therapeutics plc | Krystexxa | $163 | 12 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $60 | 2 payments
|
| Vifor Pharma | Veltassa | $39 | 2 payments
|
| OPKO Pharmaceuticals | Rayaldee | $34 | 2 payments
|
| Travere Therapeutics | None | $33 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $30 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $23 | 1 payment
|
| GlaxoSmithKline | Benlysta | $17 | 1 payment
|
2021: $193
| AstraZeneca Pharmaceuticals LP | Farxiga | $125 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $35 | 2 payments
|
| Otsuka America Pharmaceutical | Jynarque | $19 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $14 | 1 payment
|
2020: $160
| Otsuka America Pharmaceutical | Jynarque | $50 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $35 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $23 | 1 payment
|
| Relypsa | Veltassa | $19 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $18 | 1 payment
|
| Amarin Pharma | Vascepa | $15 | 1 payment
|
2019: $365
| OPKO Pharmaceuticals | Rayaldee | $113 | 12 payments
|
| Relypsa | Veltassa | $66 | 3 payments
|
| Otsuka America Pharmaceutical | Jynarque | $42 | 2 payments
|
| Mallinckrodt Enterprises | Acthar | $33 | 1 payment
|
| Pfizer | Eliquis | $25 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $25 | 1 payment
|
| Alexion Pharmaceuticals | Soliris | $23 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $19 | 1 payment
|
| GlaxoSmithKline | Anoro | $19 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| CSL Behring · A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study To Investigate the Efficacy and Safety of Csl300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis · 2024 | Their institution | $21,825 |
Professional record
- NPI
- 1104003458
- Licence
- CA A99851California A99851: Current · expires 2027-05-31
- Trained
- Loyola University of Chicago, Stritch School of Medicine, 2005 · 21 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 10605 Balboa Blvd, 240, Granada Hills, CA, 91344
- NPI first listed
- 2008-01-29
- NPI last updated
- 2014-01-28
This is when the NPI record was last certified, not a medical board exam.